Theralase Technologies announced its lead compound TLD-1433 in a combination with Rutherrin showed an ability to eliminate different versions of lung cancer.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced its lead compound TLD-1433 in a combination with Rutherrin showed an ability to eliminate different versions of lung cancer.
As quoted in the press release:
TLD-1433, in combination with transferrin (Rutherrin®) has been shown to selectively accumulate in cancerous tumors versus healthy tissue, due to localization through the Tf-R.
Each type of NSCLC has different kinds of cancer cells. The cancer cells of each type grow and spread in different ways. The types of NSCLC are named for the kinds of cells found in cancer and how the cells look under a microscope:
- Squamous cell carcinoma: Cancer that begins in squamous cells, which are thin, flat cells that look like fish scales, also called epidermoid carcinoma.
- Large cell carcinoma: Cancer that may begin in several types of large cells.
- Adenocarcinoma: Cancer that begins in the cells that line the alveoli and produce substances such as mucus.
In preclinical experiments conducted by the team of Kazuhiro Yasufuku MD, PhD, Director of Endoscopy and the Director of Interventional Thoracic Surgery Program in the Division of Thoracic Surgery, Toronto General Hospital, University Health Network (“UHN“), as well as an Associate Professor of Surgery at the University of Toronto, an evaluation of the TfR by flow cytometric analysis in three human cancer cell lines; specifically: H2170 (lung squamous cell carcinoma), H460 (large cell lung cancer carcinoma) and A549 (lung adeno carcinoma) showed almost 100% of lung cancer cells express the TfR.